High-Risk Cancer Clinical Trial
Official title:
A Phase 2, Multicenter, Single Arm Trial to Assess the Safety and Efficacy of a Pediatric Approach to for Young Adults With Acute Lymphoblastic Leukemia With Blinatumomab Therapy for High-risk Patients Prior to Allogeneic Transplantation
Despite recent therapeutic advancements, the outcome of young adults with Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) remains unsatisfactory, especially in those patients with high-risk disease features. In young adults pediatric-based chemotherapy approaches improve outcome. Furthermore, there is evidence that pre-transplant antibody-based therapy may render patients with positive minimal residual disease (MRD+) to an MRD-negative status (MRD-) and that this may be associated with improved post-transplant outcome. This is prospective study to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be performed.
This is a national, multicenter, phase II clinical trial to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be assessed. Young-adult patients eligible with Ph-neg ALL, LBL and mixed phenotype acute leukemia (MPAL) will undergo risk stratification and started on the pediatric Italian Association of Pediatric Hematology Oncology-Berlin-Frankfurt-Münster (AIEOP-BFM) 2009 protocol. Patients defined as having non-high-risk disease features (non-HR) as defined by MRD and/or cytogenetic criteria will complete the non-HR chemotherapy arm per protocol. Patients designated as having HR disease features after 2 induction blocks will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation. All patients will be centrally assessed for MRD and for Ph-like status. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06041490 -
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
|
Phase 2 | |
Recruiting |
NCT03978663 -
Three Fraction Radiation to Induce Immuno-Oncologic Response
|
N/A | |
Withdrawn |
NCT05120622 -
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05254899 -
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
|
Phase 2 | |
Recruiting |
NCT04947098 -
Prevent Cancer- Greenville
|
||
Recruiting |
NCT06020443 -
Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France.
|
N/A | |
Completed |
NCT02308280 -
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT06046625 -
Needs and Preferences of Patients With Head-neck Cutaneous SCC
|
||
Recruiting |
NCT06277050 -
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT03343249 -
Adjunctive Smart Phone Based Smoking Cessation Treatment
|
N/A | |
Recruiting |
NCT06327568 -
Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
|
||
Terminated |
NCT01941550 -
Neoadjuvant Chemotherapy With Cabazitaxel
|
Phase 2 | |
Recruiting |
NCT05482880 -
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
|
||
Recruiting |
NCT05498272 -
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
|
Phase 2 | |
Terminated |
NCT01479192 -
Fenretinide in Healthy Young Women at Genetic and Familial Risk
|
Phase 3 | |
Recruiting |
NCT05557487 -
Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
|
||
Recruiting |
NCT04217356 -
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
|
||
Recruiting |
NCT04740866 -
Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer
|
N/A | |
Recruiting |
NCT04905329 -
A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
|
||
Active, not recruiting |
NCT01827137 -
WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
|
N/A |